Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer
NCT03912818Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in bladder cancer, sponsored by Stanford University. Started Apr 2019; status: terminated.
02
Drugs
durvalumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03912818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912818.